Evidence map›Paper›PMID 34674018›Full record

ArticleWorld journal of urology2022

Transrectal ultrasound-guided prostate needle biopsy remains a safe method in confirming a prostate cancer diagnosis: a multicentre Australian analysis of infection rates.

Cameron J Parkin, Daniel Gilbourd, Richard Grills, Sue Chapman, Sydney Weinstein, Neil Joshi, Balasubramaniam Indrajit, Jonathan Kam, Teresa Smilovic, Andrew Shepherd and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Cameron J ParkinDepartment of Urology, Gosford Hospital, Central Coast Local Health District, Holden St, Gosford, NSW, 2250, Australia. cameronjparkin@gmail.com.ORCID http://orcid.org/0000-0001-6294-2368
Daniel GilbourdCalvary Hospital, Bruce, ACT, Australia.
Richard GrillsDepartment of Surgery, Deakin University, Geelong, VIC, Australia.
Sue ChapmanSt. John of God Bunbury Hospital, College Grove, WA, Australia.
Sydney WeinsteinHollywood Private Hospital, Nedlands, WA, Australia.
Neil JoshiCoffs Harbour Health Campus, Coffs Harbour, NSW, Australia.
Balasubramaniam IndrajitDubbo Base Hospital, Dubbo, NSW, Australia.
Jonathan KamCalvary Hospital, Bruce, ACT, Australia.
Teresa SmilovicWest Coast Urology, Geelong, VIC, Australia.
Andrew ShepherdSt. John of God Bunbury Hospital, College Grove, WA, Australia.
Njeri GikenyeCoffs Harbour Health Campus, Coffs Harbour, NSW, Australia.
Mark W Louie-JohnsunDepartment of Urology, Gosford Hospital, Central Coast Local Health District, Holden St, Gosford, NSW, 2250, Australia.
Calvary Hospital · AUCoffs Harbour City Council · AUGosford Hospital · AUDeakin University · AUDubbo Hospital · AUHollywood Private Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWorldwide, transrectal ultrasound-guided prostate needle remains the most common method of diagnosing prostate cancer. Due to high infective complications reported, some have suggested it is now time to abandon this technique in preference of a trans-perineal approach. The aim of this study was to report on the infection rates following transrectal ultrasound-guided prostate needle biopsy in multiple Australian centres. MATERIALS AND

methodsData were collected from seven Australian centres across four states and territories that undertake transrectal ultrasound-guided prostate needle biopsies for the diagnosis of prostate cancer, including major metropolitan and regional centres. In four centres, the data were collected prospectively. Rates of readmissions due to infection, urosepsis resulting in intensive care admission and mortality were recorded.

results12,240 prostate biopsies were performed in seven Australian centres between July 1998 and December 2020. There were 105 readmissions for infective complications with rates between centres ranging from 0.19 to 2.60% and an overall rate of 0.86%. Admission to intensive care with sepsis ranged from 0 to 0.23% and overall 0.03%. There was no mortality in the 12,240 cases.

conclusionInfective complications following transrectal ultrasound-guided prostate needle biopsies are very low, occurring in less than 1% of 12,240 biopsies. Though this study included a combination of both prospective and retrospective data and did not offer a comparison with a trans-perineal approach, TRUS prostate biopsy is a safe means of obtaining a prostate cancer diagnosis. Further prospective studies directly comparing the techniques are required prior to abandoning TRUS based upon infectious complications.

Indexed as

ProstateProstatic NeoplasmsAustraliaBiopsyBiopsy, NeedleHumansMaleProspective StudiesRetrospective StudiesUltrasonography, InterventionalBiopsyCritical careInfectionProstate cancerSepsisTransrectal ultrasound-guided prostate needle biopsy

Identifiers

PMID34674018
OpenAlexW3205004377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.